PEVOsq
Phase 2 Completed
112 enrolled
Vorinostat Plus Hydroxychloroquine Versus Regorafenib in Colorectal Cancer
Phase 2 Completed
42 enrolled 8 charts
N2011-01
Phase 2 Completed
114 enrolled 13 charts
MK-0683-095
Phase 2 Completed
143 enrolled 16 charts
Vorinostat in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma
Phase 2 Completed
30 enrolled 16 charts
Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer
Phase 2 Completed
18 enrolled 16 charts
Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
Phase 2 Completed
60 enrolled
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
Phase 2 Completed
32 enrolled 11 charts
Vorinostat Plus Tacrolimus & Methotrexate to Prevent Graft vs Host Disease Following Unrelated Stem Cell Transplant
Phase 2 Completed
26 enrolled 9 charts
Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma
Phase 2 Completed
30 enrolled 8 charts
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
Phase 2 Completed
12 enrolled 11 charts
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma
Phase 2 Completed
37 enrolled 8 charts
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Phase 2 Completed
16 enrolled 9 charts
Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Relapsed Chronic Lymphocytic Leukemia, or Relapsed B Cell Non-Hodgkin's Lymphoma
Phase 2 Completed
57 enrolled 14 charts
Vorinostat in Treating Patients With Kidney Cancer
Phase 2 Completed
14 enrolled 7 charts
TARGET
Phase 2 Completed
19 enrolled 12 charts
An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-cell Lymphoma (0683-013)
Phase 2 Completed
18 enrolled
Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001)
Phase 2 Completed
74 enrolled
Ph II SAHA and Bevacizumab for Recurrent Malignant Glioma Patients
Phase 2 Completed
48 enrolled 10 charts
A Continuation Clinical Trial of Oral Vorinostat (MK-0683) in Advanced Cancers (MK-0683-007)
Phase 2 Completed
27 enrolled 9 charts
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Phase 2 Completed
106 enrolled 6 charts
Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer
Phase 2 Completed
43 enrolled 8 charts
Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 2 Completed
94 enrolled 8 charts
Suberoylanilide Hydroxamic Acid in Treating Patients With Metastatic and/or Locally Advanced or Locally Recurrent Thyroid Cancer
Phase 2 Completed
19 enrolled 11 charts
Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment
Phase 2 Completed
58 enrolled 14 charts
Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer
Phase 2 Completed
29 enrolled 8 charts
Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma
Phase 2 Completed
27 enrolled 9 charts
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
Phase 2 Completed
103 enrolled 10 charts
Vorinostat in Treating Patients With Acute Myeloid Leukemia
Phase 2 Completed
37 enrolled 11 charts
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
Phase 2 Completed
44 enrolled 9 charts
Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma
Phase 2 Completed
16 enrolled 6 charts